COVID-19 patients can be categorised into three groups, say scientists
Washington: Scientists have identified three different types of COVID-19 disease traits in patients, depending on their comorbidities, complications, and clinical outcomes, an advance that may help target future interventions to the most risk-prone individuals.
The new study, published in the journal PLOS ONE, analysed the electronic health records (EHRs) from 14 hospitals in the midwestern US and from 60 primary care clinics in the state of Minnesota.
According to the researchers, including those from the University of Minnesota in the US, the study included 7,538 patients with confirmed COVID-19 between March 7 and August 25, 2020, of which 1,022 patients required hospitalisation.
Close to 60 per cent of the patients included in the research presented with what the researchers called "phenotype II."
They said about 23 per cent of the patients presented with "phenotype I," or the "adverse phenotype," which was associated with the worst clinical outcomes.
The researchers said these patients had the highest level of comorbidies related to heart and kidney dysfunction.
According to the study, 173 patients, or 16.9 per cent presented with "phenotype III," or the "favorable phenotype," which the scientists said was associated with the best clinical outcomes.
While this group had the lowest complication rate and mortality, the scientists said these patients had the highest rate of respiratory comorbidities as well as a 10 per cent greater risk of hospital readmission compared to the other phenotypes.
Overall, they said phenotypes I and II were associated with 7.30-fold and 2.57-fold increases in hazard of death relative to phenotype III.
Based on the results, the scientists said such phenotype-specific medical care could improve COVID-19 outcomes.
However, they believe further studies are needed to determine the utility of these findings in clinical practice.
"Patients do not suffer from COVID-19 in a uniform matter. By identifying similarly affected groups, we not only improve our understanding of the disease process, but this enables us to precisely target future interventions to the highest risk patients," the scientists added.
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Will Champai Soren become a game-changer for BJP in Jharkhand polls?
Ranchi: Champai Soren, a prominent figure in Jharkhand’s statehood movement, is contesting the 2024 assembly elections from Seraikela, a seat he has consistently held since 1991.
However, there is a surprising shift in his political journey this year. Having resigned from the Jharkhand Mukti Morcha (JMM) earlier this year, Soren is now representing the BJP, a move that could significantly impact the electoral dynamics in the state.
Soren’s switiching is seen as a strategic benefit for the saffron party, which has been working to expand its appeal among Jharkhand’s tribal communities, a demographic traditionally aligned with the JMM. His departure from the JMM, led by Shibu Soren and his son Hemant Soren, was fueled by dissatisfaction with the state government’s policies, which he claimed had failed to address tribal concerns.
Also known as "Jharkhand’s Tiger" for his instrumental role in the statehood movement of the 1990s, Champai Soren has respect and influence among tribal voters. His decision to switch the party could be a turning point in the BJP’s efforts to gain a stronger hold in a state where tribal votes often decide the outcome.
